Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 3.7%

Gyre Therapeutics, Inc. (NASDAQ:GYREGet Free Report) rose 3.7% during trading on Tuesday . The company traded as high as $10.88 and last traded at $10.69. Approximately 6,386 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 73,934 shares. The stock had previously closed at $10.31.

Gyre Therapeutics Stock Performance

The stock has a 50-day moving average price of $13.30 and a 200-day moving average price of $17.11.

Gyre Therapeutics (NASDAQ:GYREGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.04 earnings per share for the quarter. The firm had revenue of $27.17 million for the quarter. On average, research analysts predict that Gyre Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.

Insider Activity

In other news, Director Nassim Usman sold 20,000 shares of Gyre Therapeutics stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $14.13, for a total transaction of $282,600.00. Following the completion of the transaction, the director now directly owns 1,636 shares in the company, valued at $23,116.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 2.92% of the stock is owned by company insiders.

Gyre Therapeutics Company Profile

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.

See Also

Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.